Molecular processes that handle — and mishandle — dietary lipids by Williams, Kevin Jon
Science in medicine








































































Molecular processes that handle —  
and mishandle — dietary lipids
Kevin Jon Williams
Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine,  

















Downloaded from http://www.jci.org on December 23, 2016.   https://doi.org/10.1172/JCI35206
science in medicine




























Overview of lipid transport from gut lumen to periphery to liver. Detergents in hepatic bile, chiefly phospholipids (PL) and bile acids, emulsify lipids 
from food to form microscopic micelles within the gut lumen. Hepatic bile also contributes significant amounts of UC to these micelles. The pan-
creas secretes lipases that digest dietary lipids into chemical forms that can be absorbed by the gut epithelium, e.g., NEFAs, monoacylglycerides, 
and UC. Absorption of fatty acids and monoacylglycerides approaches 100% efficiency and occurs via passive diffusion and carrier-mediated 
processes (64). Cholesterol absorption averages about 50% efficiency with considerable interindividual variation. Enterocytes reesterify these 
lipids intracellularly and then package them into large particles, CMs, that are rich in triglycerides (TG) but also contain substantial amounts of 
UC and cholesteryl esters. These particles are secreted into thoracic lymph, which drains directly into the systemic bloodstream, bypassing the 
liver. The mixed lipid composition of CMs leads to a 2-step clearance process. First, when these particles reach the capillary beds of peripheral 
tissues, a key metabolic branch point occurs between energy storage in adipose tissue (blue arrows) and lipid combustion in striated muscle 
(green arrows). In a regulated fashion, CMs dock on the microvascular endothelium of these tissues, where LpL hydrolyzes CM triglycerides 
into NEFAs to deliver lipid calories for local use. In the second step of clearance, residual triglyceride-depleted, cholesteryl ester–rich particles, 
now called CM remnant lipoproteins, are released back into plasma. Under normal circumstances, the liver rapidly and safely removes them 
from the circulation (red arrows).
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Dysregulated mediators of lipid and lipoprotein trafficking in diabetes, obesity, and related conditions
Molecule/process	 Dysregulation	 Likely	consequences
NPC1L1, ABCG5/G8 In diabetes, increased intestinal and hepatic  Increased intestinal cholesterol absorption, decreased  
 expression of Npc1l1 (28) and decreased  hepatic biliary cholesterol excretion, and increased  
 intestinal expression of ABCG5/G8 (28–30) cholesterol content of secreted CMs and VLDL
MTP Intestinal overexpression in intestinal  Substantially increased intestinal secretion of apoB48,  
 insulin resistance (15) and diabetes (28, 30) hence an increased number of secreted particles
Intestinal lipid synthesis Increased synthesis of fatty acids, triglycerides,  Increased CM secretion in insulin  
 and cholesteryl esters by enterocytes  resistance and overt diabetes (67) 
 in intestinal insulin resistance (15)
LpL Increased activity in adipose tissue, but decreased  Diversion of CM and VLDL calories into  
 activity in striated muscle, in the fed  adipose depots for storage and away  
 and sedentary states (3, 78, 79) from combustion in muscle
Angiopoietin-like proteins Suppressed expression in adipose  Diversion of CM and VLDL calories into adipose depots  
 tissue in the fed state (84) owing to a local increase in enzymatically active LpL dimers
Mitochondrial β-oxidation Reduced capacity in sedentary skeletal muscle (86) Accumulation of triglycerides and fatty acid  
  metabolites, leading to insulin resistance in muscle
Gpihbp1 Suppression of its mRNA in muscle in the fed state (90) Diversion of CM and VLDL calories away  
  from combustion in muscle
CD36 fatty acid translocase Increased expression in adipose tissue in diabetes (103) Enhanced adipose uptake of calories in the form of NEFAs
Ndst1 Suppressed mRNA, protein, and enzymatic  Defective hepatic assembly of HSPGs,  
 activity in diabetic liver (122) hence abnormal persistence of atherogenic  
  postprandial remnant lipoproteins in plasma
Ndst1, heparan sulfate N-deacetylase/N-sulfotransferase–1.
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Intestinal packaging of absorbed lipids into  
apoB48-containing lipoproteins


































Processing of dietary lipid by the enterocyte: absorption, selection, packaging, and secretion. In the apoB-dependent pathway (black arrows), 
apoB48 becomes assembled in the ER with initially small amounts of triglycerides that are synthesized mainly by DGAT2 and transferred via MTP. 
UC imported from the gut lumen into the enterocyte via NPC1L1 and possibly other proteins becomes esterified by ACAT2 and also packaged 
into the newly forming apoB48 lipoprotein. Continued lipidation in the ER inflates the particle, requiring stabilization of its surface by phospholipids 
and apoA-IV. The nascent particles are then transferred to the Golgi apparatus in noncanonical transport vesicles, further lipidated, and finally 
secreted as CMs into lymph. Some of the absorbed cholesterol and essentially all of the dietary noncholesterol sterols are pumped out of the 
enterocyte, back into the intestinal lumen for elimination from the body (blue arrows). In the apoB-independent pathway (green arrows), UC is 
absorbed into the enterocyte, and then ABCA1 facilitates its efflux from the plasma membrane onto extracellular apoA-I molecules. Movement 
onto preexisting extracellular HDL also occurs. The apoA-I originates both from local intestinal synthesis and from plasma. Absorption of NEFAs, 
monoglycerides, and lipid micronutrients across the brush border and esterification by acyl-CoA:monoacylglycerol acyltransferase enzymes are 
not shown here. CE, cholesteryl ester; PC, phosphatidylcholine; Sito, sitosterol and other noncholesterol sterols.
Downloaded from http://www.jci.org on December 23, 2016.   https://doi.org/10.1172/JCI35206
science in medicine
























































































































Downloaded from http://www.jci.org on December 23, 2016.   https://doi.org/10.1172/JCI35206
science in medicine


























CM catabolism: branch point between storage and 
combustion
Regulated hydrolysis of CM triglycerides
Enzymatically active dimers of LpL bound to the capillary endo-























































Pharmacologic strategies to inhibit apoB-dependent absorption of lipids from the gut lumen
Target	and	strategy	 Rationale
Additional NPC1L1 inhibitors Reduced intestinal absorption of biliary and dietary cholesterol, particularly in the  
 subset of poor responders to the currently available NPC1L1 inhibitor ezetimibe
Pancreatic lipase inhibitors Impaired digestion and absorption of dietary triglycerides; better adherence to low-fat diets owing  
 to abdominal discomfort after eating oils that cannot be absorbed; agents are in clinical use
MGAT2 inhibition Impaired reassembly of triglycerides within the enterocytes, which could impede CM assembly
DGAT1 inhibition Dgat1–/– mice exhibit reduced postprandial chylomicronemia, increased energy expenditure, and resistance  
 to obesity, all of which would be desirable characteristics; conversely, Dgat2–/– mice die as neonates
ACAT2 inhibition Reduced assembly of cholesteryl esters into CMs and VLDL
MTP inhibition Impaired assembly and secretion of apoB lipoproteins by intestine and liver
MGAT2, acyl-CoA:monoacylglycerol acyltransferase–2.
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Integrated model of CM binding and hydrolysis on peripheral capillary endothelium. Adipose tissue and striated muscle each synthesize LpL, 
regulated by the fasted/fed and active/sedentary metabolic states. HSPGs on the surfaces of these cells capture and internalize LpL for deg-
radation. LpL that escapes degradation will be picked up by HSPGs and VLDL receptors on the basal surface of overlying endothelial cells for 
transcytosis to the luminal surface of capillaries (orange arrows). Heparan sulfate side-chains of syndecan and glypican are denoted by chains 
of small spheres. The major HSPGs of endothelium, syndecans and glypicans, move into detergent-insoluble membrane microdomains (rafts) 
rich in caveolin-1 (CAV1) upon clustering. On the apical surface, they encounter GPIHBP1, which should also move into rafts upon clustering. 
The highly negatively charged N-terminal domain of GPIHBP1 binds LpL with approximately 10-fold greater affinity than do endothelial HSPGs. 
Thus, after transcytosis, LpL should be torn away from syndecans and glypicans onto GPIHBP1 (pink arrows). Dimers of GPIHBP1 bind LpL and 
CMs, thereby providing a platform for CM docking and triglyceride lipolysis. These processes are facilitated by apoC-II and apoA-V. Lipolysis 
generates NEFAs that are transported by another raft molecule, CD36, across the endothelium and into adipocytes for energy storage (blue 
arrows) or into striated myocytes for combustion (green arrows). After hydrolysis of CM triglycerides, the endothelium releases apoB48 remnant 
lipoproteins that are rich in LpL, apoE, and cholesteryl ester back into the circulation (red arrow). Under normal circumstances, these remnant 
particles undergo safe, swift uptake by the liver.
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Efficient hepatic uptake of CM remnant lipoproteins. Hepatic HSPGs exhibit extreme structural features of their carbohydrate side-chains that 
enhance ligand binding. Thus, HSPGs in the liver rapidly pull apoB48 remnant lipoproteins out of plasma via interactions with positively charged 
proteins on the particles, chiefly LpL and apoE. Once in the liver, the particles encounter hepatic lipase (HL), which serves as an additional bridging 
molecule between HSPGs and lipoproteins. Shown are 2 pathways for particle clearance. The first is direct receptor-mediated uptake, in which 
cholesteryl ester–rich apoB48 remnant lipoproteins pass from the hepatic sinusoid through the fenestrated endothelium and then bind directly to 
integral plasma membrane receptors (red arrows; shown are the LDL receptor, which binds apoE, and the syndecan and glypican HSPGs, which 
bind LpL, hepatic lipase, and apoE). The second clearance mechanism is a cooperative pathway, in which apoB48 remnant lipoproteins from the 
hepatic sinusoid are first sequestered by matrix HSPGs within the space of Disse and then taken up in cooperation with the integral plasma mem-
brane receptors (blue arrows; shown are the collagen XVIII and perlecan HSPGs). Also shown is one of several secreted enzymes (Enz), such as 
heparanase or the heparan 6-O-endosulfatases, that are expressed by liver, degrade HSPGs, and may dampen these processes.
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